The company announced positive Phase 3 trial results for its PADCEV and Keytruda combination in muscle-invasive bladder cancer. It also received full FDA approval for BRAFTOVI as a first-line treatment for a specific metastatic colorectal cancer, converting a prior accelerated approval. The article positions the company as an undervalued and cheap stock to buy, highlighting these new oncology drug launches as key to offsetting upcoming patent expirations on older products.